拜瑞妥怎么样？

Xarelto, also called Rivaroxaban, is produced by Bayer Healthcare Co., Ltd. Its main clinical indications are: 1. Used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE). 2. Used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT. 3. For use in adult patients with nonvalvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism. Today let’s learn about Xarelto?

An international scientific research team published a paper in the journal "The Lancet" stating that through analysis of data from a multi-center, randomized, double-blind clinical trial called "BECORD4", among a total of more than 3,000 patients, researchers confirmed that compared with standard therapy using enoxaparin, patients treated with Xarelto reduced the risk of venous thromboembolism after orthopedic surgery by about one-third. "This is the first oral anticoagulant drug with better efficacy than the current standard therapy, so it may become a new clinical treatment option for preventing severe blood clots after major orthopedic surgery," said Professor A. Turpai from McMaster University in Canada. "At the same time, this new drug also has good economics."

Venous thrombosis is a disease that both men and women are likely to suffer from, especially adult patients who have had hip or knee replacement surgery, who are more likely to suffer from this disease. Therefore, venous thrombosis should be actively prevented. Available drugs include Xarelto.

Xarelto is a highly selective, oral drug that directly inhibits factor Xa. By inhibiting factor Xa, it can interrupt the intrinsic and extrinsic pathways of the coagulation cascade and inhibit thrombin generation and thrombosis. Xarelto does not inhibit thrombin (activated factor II) and has no proven effect on platelets. A dose-dependent inhibition of factor Xa activity by Xarelto has been observed in humans. The effect of Xarelto on prothrombin time (PT) has a dose-effect relationship. If NeopLastin is used for content measurement, it is closely related to the plasma concentration (correlation coefficient is 0.98). Different results may occur with other reagents.

The above is the content of Xarelto effect, I hope it can help you!